Cryopyrin-associated periodic syndromes: Diagnosis and management

Pediatric Drugs

Volumn 14, Issue 2, 2012, Pages 109-117

  Miyamae, Takako ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Amyloidosis; Anakinra; Arthralgia; Canakinumab; Cryopyrin associated Periodic syndromes; Fever; Interleukin 1; Rilonacept; Urticaria.

Indexed keywords

CANAKINUMAB; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT;

CEREBROSPINAL FLUID EXAMINATION; CINCA SYNDROME; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EARLY DIAGNOSIS; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GENE MUTATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; INJECTION SITE REACTION; LABORATORY DIAGNOSIS; MEDICAL HISTORY; MUCKLE WELLS SYNDROME; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT INFECTION; REVIEW; SKIN MANIFESTATION; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRALGIA; ARTHRITIS, JUVENILE RHEUMATOID; AUTOIMMUNITY; CARRIER PROTEINS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DIAGNOSIS, DIFFERENTIAL; EXANTHEMA; FEVER; HUMANS; INFLAMMASOMES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MOLECULAR TARGETED THERAPY; MUTATION; PROGNOSIS; RECOMBINANT FUSION PROTEINS;

EID: 84857296761     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11595040-000000000-00000     Document Type: Review

References (38)

1. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-5 (Pubitemid 33096455)
2. Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002; 71: 198-203 (Pubitemid 34734724)
3. Aksentijevich ID, Putnam C, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007; 56: 1273-85 (Pubitemid 46608652)
4. HoffmanHM, Yasothan U, Kirkpatrick P. Fresh from the pipeline: rilonacept. Nat Rev Drug Discov 2008; 7: 385-6
5. Lainka E, Neudorf U, Lohse P, et al. Analysis of cryopyrin-associated periodic syndromes (CAPS) in German children: epidemiological, clinical and genetic characteristics. Klin Padiatr 2010; 222: 356-61
6. Cuisset L, Jeru I,DumontB, et al.Mutations in the autoinflammatory cryopyrinassociated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis 2011; 70: 495-9
7. Henderson C, Goldbach-Mansky R. Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. Clin Immunol 2010; 135: 210-22
8. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006; 126: 659-62 (Pubitemid 44233635)
9. Hoffman HM, Brydges SD. The genetic and molecular basis of inflammasomemediated disease. J Biol Chem 2011; 286 (13): 10889-96
10. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-32
11. Dowds TA, Masumoto J, Zhu L, et al. Cryopyrin-induced interleukin 1beta secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC. J Biol Chem 2004; 279: 21924-8 (Pubitemid 38679382)
12. Nakamura Y, Kambe N, Saito M, et al. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine- independent urticaria. J Exp Med 2009; 206: 1037-46
13. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46: 3340-8 (Pubitemid 35453546)
14. Kile RL, Rusk HA. A case of cold urticaria with an unusual family history. JAMA 1940; 114: 1067-8
15. Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001; 108: 615-20 (Pubitemid 32978035)
16. Muckle TJ, Wells M. Urticaria, deafness, and amyloidosis: a new heredofamilial syndrome. Q J Med 1962; 31: 235-48
17. Dode C, Cuisset L, Delpech M, et al. TNFRSF1A-associated periodic syndrome (TRAPS), Muckle-Wells syndrome (MWS) and renal amyloidosis. J Nephrol 2003; 16: 435-7 (Pubitemid 36773196)
18. Prieur AM, Griscelli C. Arthropathy with rash, chronic meningitis, eye lesions, and mental retardation. J Pediatr 1981; 99: 79-83 (Pubitemid 11046422)
19. Hassink SG, Goldsmith DP. Neonatal onset multisystem inflammatory disease. Arthritis Rheum 1983; 26: 668-73 (Pubitemid 13090022)
20. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355: 581-92 (Pubitemid 44200651)
21. Prieur AM. A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheum 2001; 19: 103-6
22. Torbiak RP, Dent PB, Cockshott WP. NOMID: a neonatal syndrome of multisystem inflammation. Skeletal Radiol 1989; 18: 359-64 (Pubitemid 19207575)
23. Kaufman RA, Lovell DJ. Infantile-onset multisystem inflammatory disease: radiologic findings. Radiology 1986; 160: 741-6 (Pubitemid 16044047)
24. Hill SC, Namde M, Dwyer A, et al. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr Radiol 2007; 37: 145-52 (Pubitemid 46098444)
25. Jesus AA, Silva CA, Segundo GR, et al. Phenotype-genotype analysis of cryopyrin-associated periodic syndromes (CAPS): description of a rare nonexon 3 and a novel CIAS1 missense mutation. J Clin Immunol 2008; 28: 134-8 (Pubitemid 351328954)
26. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-71 (Pubitemid 46883770)
27. Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010; 62: 258-67
28. Miyamae T, Inaba Y, Nishimura G, et al. Effect of anakinra on arthropathy in CINCA/NOMID syndrome. Pediatr Rheumatol Online J 2010; 8: 9
29. Bywaters EG, Isdale IC. The rash of rheumatoid arthritis and Stills disease. Q J Med 1956; 25: 377-87
30. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line diseasemodifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63: 545-55
31. Quartier P, Allantaz F, Cimaz R, et al. Extended report: a multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70: 747-54
32. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006 (Pubitemid 351389534)
33. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003; 348: 2583-4
34. Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with anakinra. J Pediatr 2010; 157: 310-5
35. Stahl N, Radin A, Mellis S. Rilonacept: CAPS and beyond. Ann N Y Acad Sci 2009; 1182: 124-34
36. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58: 2443-52
37. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25
38. Novartis Pharmaceuticals. Efficacy and safety study of canakinumab administered for 6 months (24 weeks) in Japanese patients with cryopyrinassociated periodic syndromes followed by an extension phase [ClinicalTrials. gov identifier CACZ885D2308]. US National Institutes of Health, Clinical- Trials.gov [online]. Available from URL: http://www.clinicaltrials. gov [Accessed 2012 Jan 21]